[Correction of immunologic disorders in patients with burns].
Shkrob. L O LO; Lukoianova. T N TN; Vishnevskaia. S M SM; Panova. Iu M IuM; Kashin. Iu D IuD
Key Findings
- Thymalin accelerated normalization of immune markers in severe burn patients
- The strongest immune response occurred 7‑10 days after early‑started therapy
- Leukocyte transfusion gave an immediate cellular boost but didn’t sustain thymus‑dependent lymphocyte ratios
Practical Outcomes
- For most self‑experimenters, the results aren’t directly usable because they apply to acute burn injuries, not healthy individuals. It suggests Thymalin might aid immune recovery after major trauma, but more research is needed before considering it for general longevity or performance protocols.
Summary
The study found that giving Thymalin, a thymus‑derived peptide, to patients with severe burns helped their immune system recover faster, especially when started early, with the biggest improvements seen about a week after treatment. Adding a blood leukocyte transfusion also gave a short‑term boost but didn’t keep the immune balance stable.
Abstract
Addition of immunomodulating therapy with Thymalin, a thymus agent, to the multimodality therapy of burnt patients contributes to a rapid normalization of immunological parameters. The most marked immune response was observed 7-10 days after a therapy course initiated in the early periods of burn disease in patients with severely depressed T-system immunity and a high sensitivity to the drug. Inclusion of a donor blood leukomass transfusion course activates the cellular link of the immune system just after the treatment course, but fails to favour a stable normalization of thymus-dependent lymphocyte ratios.
Study Information
pubmed
1990